Ausgabe 5/2016
Inhalt (15 Artikel)
The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line
Raffaele Pezzani, Beatrice Rubin, Loris Bertazza, Marco Redaelli, Susi Barollo, Halenya Monticelli, Enke Baldini, Caterina Mian, Carla Mucignat, Carla Scaroni, Franco Mantero, Salvatore Ulisse, Maurizio Iacobone, Marco Boscaro
In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118
Eduardo J. Salustiano, Matheus L. Dumas, Gabriel G. Silva-Santos, Chaquip D. Netto, Paulo R. R. Costa, Vivian M. Rumjanek
Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
Magdalena Kusaczuk, Rafał Krętowski, Anna Stypułkowska, Marzanna Cechowska-Pasko
Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors
Cynthia M. Nijenhuis, Edward Hellriegel, Jos H. Beijnen, Diane Hershock, Alwin D. R. Huitema, Luc Lucas, Marja Mergui-Roelvink, Mihaela Munteanu, Laura Rabinovich-Guilatt, Philmore Robertson Jr., Hilde Rosing, Ofer Spiegelstein, Jan H. M. Schellens
Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)
Amy Prawira, Irene Brana-Garcia, Anna Spreafico, Andrew Hope, John Waldron, Albiruni R. Abdul Razak, Eric X Chen, Raymond Jang, Brian O’Sullivan, Meredith Giuliani, Andrew Bayley, John Cho, Lisa Wang, Bayardo Perez-Ordonez, Ilan Weinreb, Lillian L. Siu, Aaron R Hansen
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
Kiyotaka Yoh, Toshihiko Doi, Hironobu Ohmatsu, Takashi Kojima, Hideaki Takahashi, Yoshitaka Zenke, Volker Wacheck, Sotaro Enatsu, Takashi Nakamura, Kellie Turner, Kazunori Uenaka
Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
Hidenori Mizugaki, Noboru Yamamoto, Haruyasu Murakami, Hirotsugu Kenmotsu, Yutaka Fujiwara, Yoshimasa Ishida, Tomohisa Kawakami, Toshiaki Takahashi
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
Lee S. Rosen, Patricia LoRusso, Wen Wee Ma, Jonathan W. Goldman, Amy Weise, A. Dimitrios Colevas, Alex Adjei, Salim Yazji, Angela Shen, Stuart Johnston, Hsin-Ju Hsieh, Iris T. Chan, Branimir I. Sikic
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia
Karen W. L. Yee, Hsiao-Wei T. Chen, David W. Hedley, Sue Chow, Joseph Brandwein, Andre C. Schuh, Aaron D. Schimmer, Vikas Gupta, Deborah Sanfelice, Tara Johnson, Lisa W. Le, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Mark D. Minden
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
Giorgio Scagliotti, Jin Hyoung Kang, David Smith, Richard Rosenberg, Keunchil Park, Sang-We Kim, Wu-Chou Su, Thomas E. Boyd, Donald A. Richards, Silvia Novello, Scott M. Hynes, Scott P. Myrand, Ji Lin, Emily Nash Smyth, Sameera Wijayawardana, Aimee Bence Lin, Mary Pinder-Schenck
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites
Naminatsu Takahara, Hiroyuki Isayama, Yousuke Nakai, Hironori Ishigami, Sohei Satoi, Suguru Mizuno, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Hironori Yamaguchi, Minoru Tada, Joji Kitayama, Toshiaki Watanabe, Kazuhiko Koike
The renal effects of ALK inhibitors
Hassan Izzedine, Rania Kheder El-Fekih, Mark A. Perazella
Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy
Farzan Kianersi, Heshmatollah Ghanbari, Zahra Naderi Beni, Afsaneh Naderi Beni
Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors
Noura Benslama, Julien Bollard, Cécile Vercherat, Patrick Massoma, Colette Roche, Valérie Hervieu, Julien Peron, Catherine Lombard-Bohas, Jean-Yves Scoazec, Thomas Walter
Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine–induced apoptosis in neuroblastoma cells
Jennifer C. Lennon, Stefania Butini, Giuseppe Campiani, Anne O’Meara, D. Clive Williams, Daniela M. Zisterer